Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Chronic Heart Failure

Free Subscription 11.07.2022 1 Am J Cardiol 1 Basic Res Cardiol 1 Cardiovasc Res 7 Clin Cardiol 2 Eur Heart J 21 Eur J Heart Fail 4 Int J Cardiol 3 J Am Coll Cardiol 1 J Cardiovasc Pharmacol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Cardiol

1. AKHTAR KH, Johnston S, Zhao YD, Amil F, et al
   Meta-analysis Analyzing the Effect of Therapies on 6-Minute Walk Distance in Heart Failure With Reduced Ejection Fraction.
   Am J Cardiol. 2022 Jun 27. pii: S0002-9149(22)00585.
   PubMed         Abstract available
   
   

   
   Basic Res Cardiol

2. ASHRAF S, Taegtmeyer H, Harmancey R
   Prolonged cardiac NR4A2 activation causes dilated cardiomyopathy in mice.
   Basic Res Cardiol. 2022;117:33.
   PubMed         Abstract available
   
   

   
   Cardiovasc Res

3. KEEFE J, Wehrens XH, Dobrev D
   Common disease-promoting signaling pathways in heart failure and atrial fibrillation: putative underlying mechanisms and potential therapeutic consequences.
   Cardiovasc Res. 2022 Jul 5. pii: 6631397. doi: 10.1093.
   PubMed        
   
   

   
   Clin Cardiol

4. HAMMOND MM, Everitt IK, Khan SS
   New strategies and therapies for the prevention of heart failure in high-risk patients.
   Clin Cardiol. 2022;45 Suppl 1:S13-S25.
   PubMed         Abstract available
   
   
5. OSTROMINSKI JW, Vaduganathan M
   Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.
   Clin Cardiol. 2022;45 Suppl 1:S40-S51.
   PubMed         Abstract available
   
   
6. FONAROW GC
   Advances in the management of heart failure.
   Clin Cardiol. 2022;45 Suppl 1:S1.
   PubMed        
   
   
7. CHANDRAMOULI C, Stewart S, Almahmeed W, Lam CSP, et al
   Clinical implications of the universal definition for the prevention and treatment of heart failure.
   Clin Cardiol. 2022;45 Suppl 1:S2-S12.
   PubMed         Abstract available
   
   
8. MCMURRAY JJV, Docherty KF
   Insights into foundational therapies for heart failure with reduced ejection fraction.
   Clin Cardiol. 2022;45 Suppl 1:S26-S30.
   PubMed         Abstract available
   
   
9. TALHA KM, Butler J
   Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction.
   Clin Cardiol. 2022;45 Suppl 1:S31-S39.
   PubMed         Abstract available
   
   
10. DEVORE AD, Bosworth HB, Granger BB
    Improving implementation of evidence-based therapies for heart failure.
    Clin Cardiol. 2022;45 Suppl 1:S52-S59.
    PubMed         Abstract available
    
    

    
    Eur Heart J

11. DOEHNER W, Anker SD, Butler J, Zannad F, et al
    Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Eur Heart J. 2022 Jul 5. pii: 6631286. doi: 10.1093.
    PubMed         Abstract available
    
    
12. GARG P, Gosling R, Swoboda P, Jones R, et al
    Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications.
    Eur Heart J. 2022;43:2511-2522.
    PubMed         Abstract available
    
    

    
    Eur J Heart Fail

13. VON OLSHAUSEN G, Benson L, Dahlstrom U, Lund LH, et al
    Catheter Ablation for Patients with Atrial Fibrillation and Heart Failure: Insights from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Jul 2. doi: 10.1002/ejhf.2604.
    PubMed         Abstract available
    
    
14. VRTOVEC B, Frljak S, Poglajen G, Zemljic G, et al
    A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION.
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2596.
    PubMed         Abstract available
    
    
15. MARCO GUAZZI M, Wilhelm M, Halle M, Van Craenenbroeck E, et al
    Exercise Testing in HFpEF: an Appraisal Through Diagnosis, Pathophysiology and Therapy A Clinical Consensus Statement of the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2601.
    PubMed         Abstract available
    
    
16. RYAN M, Perera D, Petrie MC
    Revascularization and heart failure with preserved ejection fraction - time for randomized trials.
    Eur J Heart Fail. 2022 Jun 21. doi: 10.1002/ejhf.2583.
    PubMed        
    
    
17. AIMO A, Castiglione V, Bayes-Genis A
    Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2580.
    PubMed        
    
    
18. LEYVA F, Boriani G
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1091-1093.
    PubMed        
    
    
19. COOPER LT JR
    Sex and autoimmunity in acute myocarditis: time for a refresh.
    Eur J Heart Fail. 2022;24:1045-1046.
    PubMed        
    
    
20. CLELAND JGF, Bristow MR, Freemantle N, Olshansky B, et al
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1080-1090.
    PubMed         Abstract available
    
    
21. YAMAMOTO M, Tajiri K, Ayuzawa S, Ieda M, et al
    Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination.
    Eur J Heart Fail. 2022;24:1132-1138.
    PubMed         Abstract available
    
    
22. BARITUSSIO A, Schiavo A, Basso C, Giordani AS, et al
    Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies.
    Eur J Heart Fail. 2022;24:1033-1044.
    PubMed         Abstract available
    
    
23. GONZALEZ A, Richards AM, de Boer RA, Thum T, et al
    Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022;24:927-943.
    PubMed         Abstract available
    
    
24. MARTENS P, Dupont M, Dauw J, Nijst P, et al
    The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
    Eur J Heart Fail. 2022;24:1106-1113.
    PubMed         Abstract available
    
    
25. CHIANG CH, Chiang CH, Chiang CH
    Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'.
    Eur J Heart Fail. 2022;24:1142-1143.
    PubMed        
    
    
26. MCDOWELL K, Welsh P, Docherty KF, Morrow DA, et al
    Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
    Eur J Heart Fail. 2022;24:1066-1076.
    PubMed         Abstract available
    
    
27. KRISTENSEN SL, Barasa A, Thune JJ
    The Challenge of Addressing Heart Failure in Low and Middle Income Countries.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2598.
    PubMed        
    
    
28. GULIZIA MM, Orso F, Mortara A, Lucci D, et al
    BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines.
    Eur J Heart Fail. 2022 Jul 3. doi: 10.1002/ejhf.2605.
    PubMed         Abstract available
    
    
29. WANG X, Cunningham JW
    Restoring Balance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2599.
    PubMed        
    
    
30. SENNI M, Alemayehu WG, Sim D, Edelmann F, et al
    Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2608.
    PubMed         Abstract available
    
    
31. MERKELY B, Geller L, Zima E, Osztheimer I, et al
    Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2609.
    PubMed         Abstract available
    
    
32. POCOCK SJ, Ferreira JP, Packer M, Zannad F, et al
    Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2022 Jul 7. doi: 10.1002/ejhf.2607.
    PubMed         Abstract available
    
    
33. TOMASONI D, Adamo M, Metra M
    June 2022 at a glance: prevention, outcomes and treatment.
    Eur J Heart Fail. 2022;24:913-915.
    PubMed        
    
    

    
    Int J Cardiol

34. YANO M, Nishino M, Ukita K, Kawamura A, et al
    Clinical impact of blood urea nitrogen, regardless of renal function, in heart failure with preserved ejection fraction.
    Int J Cardiol. 2022 Jun 29. pii: S0167-5273(22)01014.
    PubMed         Abstract available
    
    
35. YOUNES AM, Salem M, Maraey A, Nomigolzar S, et al
    Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis.
    Int J Cardiol. 2022 Jun 28. pii: S0167-5273(22)01012.
    PubMed         Abstract available
    
    
36. SWARTZ AM, Wamsley C, Crownover E, Tarima S, et al
    Move more and sit less pilot intervention for individuals with heart failure.
    Int J Cardiol. 2022 Jul 1. pii: S0167-5273(22)01023.
    PubMed         Abstract available
    
    
37. SHAMAKI GR, Kesiena O, Markson F, Andrew M, et al
    Editorial of "Heart failure with normal LVEF in BIOSTAT-CHF" to International Journal of Cardiology".
    Int J Cardiol. 2022 Jul 1. pii: S0167-5273(22)01021.
    PubMed        
    
    

    
    J Am Coll Cardiol

38. FLORIDO R, Daya NR, Ndumele CE, Koton S, et al
    Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study.
    J Am Coll Cardiol. 2022;80:22-32.
    PubMed         Abstract available
    
    
39. AMBROSY AP, Parikh RV, Sung SH, Tan TC, et al
    Analysis of Worsening Heart Failure Events in an Integrated Health Care System.
    J Am Coll Cardiol. 2022;80:111-122.
    PubMed         Abstract available
    
    
40. JANUZZI JL JR, Butler J
    The Importance of Worsening Heart Failure: Hiding in Plain Sight.
    J Am Coll Cardiol. 2022;80:123-125.
    PubMed        
    
    

    
    J Cardiovasc Pharmacol

41. GITTO M, Kotinas AS, Terzi R, Oliva A, et al
    Biochemical efficacy of sodium-glucose cotransporter 2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population.
    J Cardiovasc Pharmacol. 2022 Apr 14. pii: 00005344-990000000-00025.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: